Acurx Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
ACXP$1.04-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
| (a) | The financial statements filed as part of this Form 10-K are listed in the Index to Financial Statements. Certain schedules are omitted because they are not applicable, or not required, or because the required information is included in the financial statements or notes thereto. The Exhibits are listed in Item 15(b) below. |
| (b) | Exhibit Index. |
| ExhibitNumber · Exhibit Description · FiledHerewith · IncorporatedbyReferencehereinfrom Form orSchedule · FilingDate · SEC File/RegistrationNumber | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3.1 | | Certificate of Incorporation of Acurx Pharmaceuticals, Inc. | | | | 10-K | | 03/15/24 | | 001-40536 |
| 3.2 | | Bylaws of Acurx Pharmaceuticals, Inc. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 4.1 | | Form of Common Stock Certificate. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 4.2 | | Form of Series A Warrant. | | | | 8-K | | 07/25/22 | | 001-40536 |
| 4.3 | | Form of Series B Warrant. | | | | 8-K | | 07/25/22 | | 001-40536 |
| 4.4 | | Form of Placement Agent Warrant. | | | | 8-K | | 07/25/22 | | 001-40536 |
| 4.5 | | Form of Series C Warrant. | | | | 8-K | | 05/17/23 | | 001-40536 |
| 4.6 | | Form of Series D Warrant. | | | | 8-K | | 05/17/23 | | 001-40536 |
| 4.7 | | Form of 2023 Pre-Funded Warrant. | | | | 8-K | | 05/17/23 | | 001-40536 |
| 4.8 | | Form of Series E Warrant | | | | 8-K | | 01/07/25 | | 001-40536 |
| 4.9 | | Form of January 2025 Wainwright Warrant | | | | 8-K | | 01/07/25 | | 001-40536 |
| 4.10 | | Form of Series F Warrant | | | | 8-K | | 03/10/25 | | 001-40536 |
| 4.11 | | Form of Pre-Funded Warrant | | | | 8-K | | 03/10/25 | | 001-40536 |
| 4.12 | | Form of March 2025 Wainwright Warrant | | | | 8-K | | 03/10/25 | | 001-40536 |
| 4.13 | | Description of Securities. | | X | | | | | | |
| 10.1 | | Form of Indemnification Agreement. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 10.2 | | Form of Warrant. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 10.3 | | Form of Common Stock Purchase Warrant. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 10.4 | | Form of Securities Purchase Agreement. | | | | 8-K | | 07/25/22 | | 001-40536 |
| 10.5 | | Form of Investor Rights Agreement, by and between the Registrant and certain purchasers. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 10.6.1+ | | Acurx Pharmaceuticals, Inc. 2021 Equity Incentive Plan. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 10.6.2+ | | Form of Stock Option Agreement under the 2021 Equity Incentive Plan. | | | | S-8 | | 07/19/21 | | 333-258026 |
| 10.6.3+ | | Form of Restricted Stock Agreement under the 2021 Equity Incentive Plan. | | | | S-8 | | 07/19/21 | | 333-258026 |
| 10.6.4+ | | Form of Recapitalization Exchange Option Agreement. | | | | S-8 | | 07/19/21 | | 333-258026 |
| ExhibitNumber · Exhibit Description · FiledHerewith · IncorporatedbyReferencehereinfrom Form orSchedule · FilingDate · SEC File/RegistrationNumber | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 10.7+ | | Amended and Restated Employment Agreement, by and between Acurx Pharmaceuticals, Inc. and Robert J. DeLuccia, dated May 25, 2021. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 10.8+ | | Amended and Restated Employment Agreement, by and between Acurx Pharmaceuticals, Inc. and David P. Luci, dated May 25, 2021. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 10.9+ | | Amended and Restated Employment Agreement, by and between Acurx Pharmaceuticals, Inc. and Robert Shawah, dated May 25, 2021. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 10.10 | | Master Clinical Services Agreement, dated October 11, 2019, by and between Acurx Pharmaceuticals, Inc. and Syneos Health, LLC. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 10.11 | | Asset Purchase Agreement, dated February 5, 2018, by and between Acurx Pharmaceuticals, Inc. and GLSynthesis Inc. | | | | S-1 | | 05/27/21 | | 333-256516 |
| 10.12 | | Form of Securities Purchase Agreement, dated as of May 16, 2023, by and between Acurx. Pharmaceuticals, Inc. and the investor | | | | 10-Q | | 08/11/23 | | 001-40536 |
| 10.13 | | Form of Warrant Amendment Agreement, dated as of May 16, 2023, by and between Acurx. Pharmaceuticals, Inc. and the investor | | | | 8-K | | 05/17/23 | | 001-40536 |
| 10.14 | | Sales Agreement, dated as of November 15, 2023, between Acurx Pharmaceuticals, Inc. and A.G.P/Alliance Global Partners. | | | | 8-K | | 11/15/23 | | 001-40536 |
| 10.15 | | Form of Securities Purchase Agreement, dated as of January 6, 2025, by and among Acurx Pharmaceuticals, Inc. and the purchasers party thereto. | | | | 8-K | | 01/07/25 | | 001-40536 |
| 10.16 | | Form of Securities Purchase Agreement, dated as of March 6, 2025, by and between Acurx Pharmaceuticals, Inc. and the purchaser party thereto. | | | | 8-K | | 03/10/25 | | 001-40536 |
| 19.1 | | Acurx Pharmaceuticals, Inc. Insider Trading Policy. | | X | | | | | | |
| 21.1 | | Subsidiaries. | | X | | | | | | |
| 23.1 | | Consent of CohnReznick LLP. | | X | | | | | | |
| ExhibitNumber · Exhibit Description · FiledHerewith · IncorporatedbyReferencehereinfrom Form orSchedule · FilingDate · SEC File/RegistrationNumber | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 31.1 | | Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | X | | | | | | |
| 31.2 | | Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | X | | | | | | |
| 32.1 | | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | X | | | | | | |
| 32.2 | | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | X | | | | | | |
| 97.1 | | Acurx Pharmaceuticals, Inc. Clawback Policy. | | | | 10-K | | 03/15/24 | | 001-40536 |
| 101.INS | | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | | X | | | | | | |
| 101.SCH | | Inline XBRL Taxonomy Extension Schema Document. | | X | | | | | | |
| 101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | | X | | | | | | |
| 101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document. | | X | | | | | | |
| 101.LAB | | Inline XBRL Taxonomy Extension Labels Linkbase Document. | | X | | | | | | |
| 101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | | X | | | | | | |
| 104 | | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit). | | X | | | | | | |
| # | Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (“[***]”) because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed. |
|---|
| + | Denotes management compensation plan or contract. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.